Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sitagliptin/Metformin in Healthy Chinese Subjects
NCT04877106Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Plasma Concentration at 80 days, Area Under the Curve from time 0 to last measurable concentration at 80 days and 1 more. Started Apr 2018; status: completed.
02
Drugs
sitagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04877106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877106.